Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Learn more about whether Corcept Therapeutics Incorporated or Royalty Pharma plc is a better investment based on AAII's A+ ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...